Compare Summit Therapeutics Inc (SMMT) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF (XDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Summit Therapeutics Inc trades at $15.25 (market cap $12.06B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $39.44. The key difference: Roundhill S&P 500 0DTE Covered Call Strategy ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | XDTE | |
|---|---|---|
Market Cap | $12.06B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $26.98 | $44.76 |
52-Week Low | $12.55 | $36.00 |
Enterprise Value | $11.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.
The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Roundhill S&P 500 0DTE Covered Call Strategy ETF
XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →
